Free Trial

Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals logo
$0.18 0.00 (0.00%)
As of 11/6/2026

AMPE vs. EVFM, PRFX, NXTS, SBFM, and IMCC

Should you buy Ampio Pharmaceuticals stock or one of its competitors? Ampio Pharmaceuticals's main competitors and comparable companies include Evofem Biosciences (EVFM), PainReform (PRFX), Nexentis Technologies (NXTS), Sunshine Biopharma (SBFM), and IM Cannabis (IMCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ampio Pharmaceuticals compare to Evofem Biosciences?

Ampio Pharmaceuticals (NYSE:AMPE) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.41, indicating that its share price is 241% less volatile than the broader market.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Evofem Biosciences Neutral

Evofem Biosciences has higher revenue and earnings than Ampio Pharmaceuticals. Evofem Biosciences is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Evofem Biosciences$11.39M0.07$52.98M-$0.13N/A

Ampio Pharmaceuticals has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Ampio Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Evofem Biosciences -46.42%-91.97%-61.93%

Summary

Ampio Pharmaceuticals beats Evofem Biosciences on 6 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to PainReform?

PainReform (NASDAQ:PRFX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

PainReform has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PainReform$31K21.94-$5.02M-$736.66N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, PainReform had 2 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 2 mentions for PainReform and 0 mentions for Ampio Pharmaceuticals. PainReform's average media sentiment score of 0.89 beat Ampio Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company Overall Sentiment
PainReform Positive
Ampio Pharmaceuticals Neutral

PainReform has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

37.3% of PainReform shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
PainReformN/A N/A N/A
Ampio Pharmaceuticals N/A N/A N/A

Summary

PainReform beats Ampio Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Nexentis Technologies?

Ampio Pharmaceuticals (NYSE:AMPE) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nexentis Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Nexentis Technologies had 4 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 4 mentions for Nexentis Technologies and 0 mentions for Ampio Pharmaceuticals. Nexentis Technologies' average media sentiment score of 0.73 beat Ampio Pharmaceuticals' score of 0.00 indicating that Nexentis Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Nexentis Technologies Positive

Ampio Pharmaceuticals' return on equity of 0.00% beat Nexentis Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Nexentis Technologies N/A -304.79%-178.91%

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Nexentis Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nexentis Technologies has higher revenue and earnings than Ampio Pharmaceuticals. Nexentis Technologies is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Nexentis Technologies$210K3.05-$4M-$96.07N/A

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

Summary

Nexentis Technologies beats Ampio Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Ampio Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.89%. Ampio Pharmaceuticals' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sunshine Biopharma-18.89% -26.55% -21.30%
Ampio Pharmaceuticals N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunshine Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Sunshine Biopharma has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market.

In the previous week, Sunshine Biopharma had 3 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 3 mentions for Sunshine Biopharma and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 beat Sunshine Biopharma's score of -0.04 indicating that Ampio Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Sunshine Biopharma Neutral
Ampio Pharmaceuticals Neutral

Sunshine Biopharma has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunshine Biopharma$36.31M0.02-$5.97M-$203.00N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 0.4% of Sunshine Biopharma shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Sunshine Biopharma on 7 of the 13 factors compared between the two stocks.

How does Ampio Pharmaceuticals compare to IM Cannabis?

IM Cannabis (NASDAQ:IMCC) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

IM Cannabis has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.01-$8.10M-$60.66N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

In the previous week, IM Cannabis had 3 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Ampio Pharmaceuticals. IM Cannabis' average media sentiment score of 1.07 beat Ampio Pharmaceuticals' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
IM Cannabis Positive
Ampio Pharmaceuticals Neutral

Ampio Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -68.64%.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-68.64% N/A -93.43%
Ampio Pharmaceuticals N/A N/A N/A

IM Cannabis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

Summary

IM Cannabis beats Ampio Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPE vs. The Competition

MetricAmpio PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$208K$13.82B$7.86B$23.24B
Dividend YieldN/A2.58%2.47%3.78%
P/E Ratio-0.0229.1634.4129.51
Price / SalesN/A7.808.093.19
Price / CashN/A15.7421.0215.64
Price / Book0.055.204.784.05
Net Income-$8.63M$2.88B$3.52B$1.08B
7 Day PerformanceN/A-3.50%-4.98%-2.88%
1 Month PerformanceN/A-3.59%-3.20%-1.00%
1 Year PerformanceN/A-7.07%-0.27%5.84%

Ampio Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat
N/AN/A$208KN/AN/A20
EVFM
Evofem Biosciences
N/A$0.01
+1.6%
N/A-31.1%$822K$11.39MN/A29
PRFX
PainReform
1.2591 of 5 stars
$0.70
-6.3%
N/A-82.5%$606K$31KN/A7
NXTS
Nexentis Technologies
1.0029 of 5 stars
$2.04
-11.5%
N/A-97.9%$590K$210KN/A9
SBFM
Sunshine Biopharma
1.0576 of 5 stars
$2.73
-0.9%
N/A-99.2%$589K$35.35MN/A50

Related Companies and Tools


This page (NYSE:AMPE) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners